"Infectious mononucleosis" flag, high-fluorescence lymphocyte percentage, and platelet-to-lymphocyte ratio as diagnostic and prognostic biomarkers for infectious mononucleosis in Chinese children

“传染性单核细胞增多症”标志、高荧光淋巴细胞百分比和血小板/淋巴细胞比值作为中国儿童传染性单核细胞增多症的诊断和预后生物标志物

阅读:1

Abstract

BACKGROUND: Infectious mononucleosis (IM) may lead to severe complications and present diagnostic challenges in certain clinical settings. This study aimed to preliminarily evaluate the clinical utility of novel CBC-derived graphical and numerical indicators as potential tools for rapid, accurate early diagnosis and monitoring of IM in children. METHODS: A total of 204 pediatric patients with IM, exhibiting a favorable prognosis, 109 pediatric patients diagnosed with other infectious diseases, and 86 healthy controls were enrolled from the Third Affiliated Hospital of Zhengzhou University. Multiple complete blood count (CBC)-derived indicators-including the machine learning-based "IM" flag, high-fluorescence lymphocyte percentage (HFLC%), and platelet-to-lymphocyte ratio (PLR)-were analyzed at initial diagnosis and on days 7, 14, and 21. RESULTS: The "IM" flag, HFLC%, and PLR were independent predictors of IM (all P < 0.01). The "IM" flag and PLR demonstrated high diagnostic efficacy across all pediatric age groups, while HFLC% showed significant diagnostic utility specifically in children over 72 months (all P < 0.001). Optimal diagnostic cutoff values were 1.95 for HFLC% and 46.35 for PLR. During follow-up, the "IM" flag gradually turned negative within 7 days (P < 0.017), HFLC% decreased significantly (all P < 0.01), whereas PLR levels showed a progressively increasing trend over 14 days (all P < 0.001). CONCLUSIONS: The "IM" flag, HFLC%, and PLR demonstrate significant diagnostic and prognostic value in pediatric IM, supporting their potential for clinical application.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。